BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 9145716)

  • 1. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
    Partin AW; Kattan MW; Subong EN; Walsh PC; Wojno KJ; Oesterling JE; Scardino PT; Pearson JD
    JAMA; 1997 May; 277(18):1445-51. PubMed ID: 9145716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
    Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
    Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
    BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomograms to predict the pathological stage of clinically localized prostate cancer in Korean men: comparison with western predictive tools using decision curve analysis.
    Jeong CW; Jeong SJ; Hong SK; Lee SB; Ku JH; Byun SS; Jeong H; Kwak C; Kim HH; Lee E; Lee SE
    Int J Urol; 2012 Sep; 19(9):846-52. PubMed ID: 22587373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.
    Makarov DV; Trock BJ; Humphreys EB; Mangold LA; Walsh PC; Epstein JI; Partin AW
    Urology; 2007 Jun; 69(6):1095-101. PubMed ID: 17572194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
    Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
    J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
    Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
    BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
    Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
    J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
    Partin AW; Yoo J; Carter HB; Pearson JD; Chan DW; Epstein JI; Walsh PC
    J Urol; 1993 Jul; 150(1):110-4. PubMed ID: 7685418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience.
    Singh P; Dogra PN; Gupta NP; Nayyar R; Seth A; Javali TD; Kumar R
    Indian J Cancer; 2011; 48(4):483-7. PubMed ID: 22293265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomograms for the prediction of pathologic stage of clinically localized prostate cancer in Korean men.
    Song C; Kang T; Ro JY; Lee MS; Kim CS; Ahn H
    J Korean Med Sci; 2005 Apr; 20(2):262-6. PubMed ID: 15831998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer--a multi-institutional update].
    Graefen M
    Aktuelle Urol; 2004 Sep; 35(5):377-8. PubMed ID: 15384003
    [No Abstract]   [Full Text] [Related]  

  • 17. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
    Blute ML; Bergstralh EJ; Partin AW; Walsh PC; Kattan MW; Scardino PT; Montie JE; Pearson JD; Slezak JM; Zincke H
    J Urol; 2000 Nov; 164(5):1591-5. PubMed ID: 11025711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
    Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
    Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor.
    Penson DF; Grossfeld GD; Li YP; Henning JM; Lubeck DP; Carroll PR
    J Urol; 2002 Apr; 167(4):1653-7; discussion 1657-8. PubMed ID: 11912382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.